Inovio Pharmaceuticals Inc (INO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Inovio Pharmaceuticals Inc stock (INO) is currently trading at $1.54. Inovio Pharmaceuticals Inc PS ratio (Price-to-Sales) is 1700.02. Analyst consensus price target for INO is $7.63. WallStSmart rates INO as Sell.
- INO PE ratio analysis and historical PE chart
- INO PS ratio (Price-to-Sales) history and trend
- INO intrinsic value — DCF, Graham Number, EPV models
- INO stock price prediction 2025 2026 2027 2028 2029 2030
- INO fair value vs current price
- INO insider transactions and insider buying
- Is INO undervalued or overvalued?
- Inovio Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- INO Piotroski F-Score and Altman Z-Score
- INO analyst price target and Smart Rating
Inovio Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Inovio Pharmaceuticals Inc (INO) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Inovio Pharmaceuticals Inc (INO) Key Strengths (0)
Supporting Valuation Data
Inovio Pharmaceuticals Inc (INO) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Revenue declining -100.00%, a shrinking business
Very expensive at 1700.0x annual revenue
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 4.5x book value
Moderate institutional interest at 49.73%
Supporting Valuation Data
Inovio Pharmaceuticals Inc (INO) Detailed Analysis Report
Overall Assessment
This company scores 14/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 0 register as strengths (avg 0/10) while 7 fall into concern territory (avg 2.1/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (1700.02), Price/Book (4.52) suggest expensive pricing. Growth concerns include Revenue Growth at -100.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -183.50%, Operating Margin at -132871.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -183.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -100.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
INO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
INO's Price-to-Sales ratio of 1700.02x trades 2817% above its historical average of 58.28x (99th percentile), historically expensive. The current valuation is 2% below its historical high of 1742.26x set in Mar 2026, and 64295% above its historical low of 2.64x in Nov 2008. Over the past 12 months, the PS ratio has expanded from ~682.0x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Inovio Pharmaceuticals Inc (INO) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Inovio Pharmaceuticals Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 65,340 with 100% decline year-over-year.
Key Findings
Debt-to-equity ratio of -1.30 indicates a conservative balance sheet with 37M in cash.
Spending 82894528% of revenue (54.2B) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -19M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 1.76, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Inovio Pharmaceuticals Inc.
Bottom Line
Inovio Pharmaceuticals Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(33 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 2:28:57 PM
About Inovio Pharmaceuticals Inc(INO)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA drugs to treat and protect people from diseases associated with the human papillomavirus (HPV), cancer, and infectious diseases.